[The first Mexican consensus of endometrial cancer. Grupo de Investigación en Cáncer de Ovario y Tumores Ginecológicos de México]

Eva Ruvalcaba-Limón, David Cantú-de-León, David Cantú de León, Eucario León-Rodríguez, Eucario León-Rodrı́guez, Patricia Cortés-Esteban, Alberto Serrano-Olvera, Alberto Serrano‐Olvera, Flavia Morales-Vásquez, Ricardo Sosa-Sánchez, Andrés Poveda-Velasco, Alejandro Crismatt-Zapata, Antonio Santillán-Gómez, Carmen Aguilar-Jiménez, Patricia Alanís-López, Paulino Alfaro-Ramírez, Miguel Ángel Álvarez-Avitia, Miguel Angel Alvarez-Avitia, Carlos Eduardo Aranda-Flores, Carlos Aranda-Flores, José Héctor Reynaldo Arias-Ceballos, Oscar Arrieta-Rodríguez, Óscar Arrieta, Eduardo Barragán-Curiel, Daniel Botello-Hernández, Rocío Brom‐Valladares, Rocío Brom-Valladares, Paula Cabrera‐Galeana, Paula Anel Cabrera-Galeana, Rafael Cantón, Juan Carlos Cantón-Romero, Daniel Capdeville-García, Jesús Cárdenas-Sánchez, Gerardo Castorena-Roji, Gerardo Castorena-Rojí, Friedman Rafael Cepeda-López, Guadalupe Cervantes-Sánchez, Lucely Cetina, Lucely de Carmen Cetina-Pérez, Jaime Alberto Coronel-Martínez, Jaime Coronel-Martínez, Seir Alfonso Cortés-Cárdenas, Juan Carlos Cruz-López, Jaime G. de la Garza-Salazar, Consuelo Díaz-Romero, Alfonso Dueñas-González, Alfonso Dueñas‐González, Aura Erazo Valle-Solís, Pedro Escudero-de los Ríos, Efrén Flores-Alvarez, Efrén Flores-Álvarez, Rolando García-Matus, Raquel Gerson-Cwilich, Aarón González-Enciso, César González-de-León, Alfonso Genaro Guevara-Torres, Guillermo Sidney Herbert-Núñez, Carlos Hernández-Hernández, Dulce Marı́a Hernández-Hernández, Dulce María Hernández-Hernández, David Isla-Ortiz, David Isla‐Ortiz, Ramiro Jesús-Sandoval, Carlos Jiménez-Cervantes, Roberto Kuri-Exsome, José Luis López-Obispo, Antonio Maffuz‐Aziz, Antonio Maffuz-Aziz, Luis Manuel Martínez-Barrera, Juan Manuel Medina-Castro, Gonzalo Montalvo‐Esquivel, Gonzalo Montalvo-Esquivel, Víctor Hugo Mora-Aguilar, Miguel Angel Morales-Palomares, Miguel Ángel Morales-Palomares, Andrés Morán-Mendoza, Gilberto Morgan-Villela, Gilberto Morgan‐Villela, Aída Mota-García, David Eduardo Muñoz-González, Dino Alberto Murillo-Cruz, Arturo Novoa-Vargas, Francisco Javier Ochoa‐Carrillo, Francisco J Ochoa-Carrillo, Luis Fernando Oñate-Ocaña, Andrea Ortega-Rojo, Alma Georgina Palacios-Martínez, Antonio Palomeque-López, María Delia Pérez-Montiel, Delia Pérez‐Montiel, Félix Quijano-Castro, Samuel Rivera-Rivera, Lesbia María Rivera-Rubí, Juan Ubaldo Robles-Flores, Amelia Rodríguez-Trejo, Efraín Salas-Gonzáles, Juan Alejandro Silva, Gilberto Solorza-Luna, Rosalía Souto-del-Bosque, Laura Leticia Tirado-Gómez, Salvador Torrescano-González, Alfonso Torres-Lobatón, Elizabeth Trejo-Durán, Verónica Villavicencio-Valencia, Verónica Villavicencio‐Valencia, Dolores Gallardo-Rincón, Dolores Gallardo‐Rincón, Grupo de Investigación en Cáncer de Ovario y Tumores Ginecológicos de México
Systematic review / meta-analysis OA: closed CC0
View on OpenAlex View on PubMed
⚙ AI-generated summary by qwen3.7-flash, 2026-09-07 ⓘ

The first Mexican consensus provides clinical recommendations for managing endometrial cancer, covering screening for high-risk patients, diagnostic procedures, surgical interventions, and adjuvant therapies to improve survival outcomes.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

INTRODUCTION: Endometrial cancer (EC) is the second most common gynecologic malignancy worldwide in the peri and postmenopausal period. Most often for the endometrioid variety. In early clinical stages long-term survival is greater than 80%, while in advanced stages it is less than 50%. In our country there is not a standard management between institutions. GICOM collaborative group under the auspice of different institutions have made the following consensus in order to make recommendations for the management of patients with this type of neoplasm. MATERIAL AND METHODS: The following recommendations were made by independent professionals in the field of Gynecologic Oncology, questions and statements were based on a comprehensive and systematic review of literature. It took place in the context of a meeting of four days in which a debate was held. These statements are the conclusions reached by agreement of the participant members. RESULTS: Screening should be performed women at high risk (diabetics, family history of inherited colon cancer, Lynch S. type II). Endometrial thickness in postmenopausal patients is best evaluated by transvaginal US, a thickness greater than or equal to 5 mm must be evaluated. Women taking tamoxifen should be monitored using this method. Abnormal bleeding in the usual main symptom, all post menopausal women with vaginal bleeding should be evaluated. Diagnosis is made by histerescopy-guided biopsy. Magnetic resonance is the best image method as preoperative evaluation. Frozen section evaluates histologic grade, myometrial invasion, cervical and adnexal involvement. Total abdominal hysterectomy, bilateral salpingo oophorectomy, pelvic and para-aortic lymphadenectomy should be performed except in endometrial histology grades 1 and 2, less than 50% invasion of the myometrium without evidence of disease out of the uterus. Omentectomy should be done in histologies other than endometriod. Surgery should be always performed by a Gynecologic Oncologist or Surgical Oncologist, laparoscopy is an alternative, especially in patients with hypertension and diabetes for being less morbid. Adjuvant treatment after surgery includes radiation therapy to the pelvis, brachytherapy, and chemotherapy. Patients with Stages III and IV should have surgery with intention to achieve optimal cytoreduction because of the impact on survival (51 m vs. 14 m), the treatment of recurrence can be with surgery depending on the pattern of relapse, systemic chemotherapy or hormonal therapy. Follow-up of patients is basically clinical in a regular basis. CONCLUSIONS: Screening programme is only for high risk patients. Multidisciplinary treatment impacts on survival and local control of the disease, including surgery, radiation therapy and chemotherapy, hormonal treatment is reserved to selected cases of recurrence. This is the first attempt of a Mexican Collaborative Group in Gynecology to give recommendations is a special type of neoplasm.

My notes (saved in your browser only)

MeSH descriptors

Carcinoma Carcinoma Carcinoma Carcinoma Carcinoma Endometrial Neoplasms Endometrial Neoplasms Endometrial Neoplasms Endometrial Neoplasms Endometrial Neoplasms Antineoplastic Agents Antineoplastic Agents Chemotherapy, Adjuvant Combined Modality Therapy Diagnostic Imaging Estrogen Antagonists Estrogen Antagonists Estrogen Replacement Therapy Estrogen Replacement Therapy Estrogens

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

openalex
last seen: 2026-05-14T07:21:23.935093+00:00
pubmed
last seen: 2026-10-08T21:08:47.456808+00:00
License: CC0 · commercial use OK